Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Non-Current Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 96.71% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 96.71% decrease, with the full-year FY2025 number at $1.7 million, down 96.71% from a year prior.
  • Other Non-Current Liabilities was $1.7 million for Q4 2025 at Myriad Genetics, roughly flat from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $51.7 million in Q4 2024 to a low of $1.7 million in Q3 2025.
  • A 5-year average of $23.6 million and a median of $27.8 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 780.43% in 2023, then tumbled 96.71% in 2025.
  • Myriad Genetics' Other Non-Current Liabilities stood at $32.1 million in 2021, then soared by 36.76% to $43.9 million in 2022, then rose by 9.57% to $48.1 million in 2023, then increased by 7.48% to $51.7 million in 2024, then crashed by 96.71% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Other Non-Current Liabilities are $1.7 million (Q4 2025), $1.7 million (Q3 2025), and $1.9 million (Q2 2025).